Table 1.
Patient and treatment-plan specifications.
| Patient # | Histology | Target volume GTV–CTV [cc] | # of fields PBS (all–reduced)/PSPT | Prescribed dose GTV–CTV [Gy] |
|---|---|---|---|---|
| 1 | Ewing sarcoma (pelvic) | 384 | 3/5 | 57.6 |
| 2 | Germinoma | 22–170 | 6–4/6 | 36.0–21.0 |
| 3 | Bladder/Prostate rhabdomyosarcoma | 41–106 | 7/7 | 50.4–30.6 |
| 4 | Ewing sarcoma (thoracic) | 7–94 | 4–3/5 | 55.8–43.2 |
| 5 | Astrocytoma | 90 | 5/5 | 52.2 |
| 6 | Ependymoma | 75–127 | 6/6 | 55.8–54.0 |
| 7 | Craniopharyngioma | 11 | 4–3/4 | 52.2 |
| 8 | Germinoma | 36–203 | 7/7 | 36.0–21.0 |
| 9 | Embryonal rhabdomyosarcoma | 61 | 6/6 | 50.4 |
| 10 | Orbital rhabdomyosarcoma | 5–7 | 4/4 | 45.0–36.0 |
| 11 | Embryonal rhabdomyosarcoma | 149 | 3/10 | 52.2 |
| 12 | Ependymoma | 12–41 | 5–3/5 | 54.0–52.2 |
| 13 | Embryonal rhabdomyosarcoma | 139–222 | 5/13 | 50.4–36.0 |
| 14 | Astrocytoma | 47 | 4–3/4 | 52.2 |